Hawthorn Berry for Heart Failure: A European Mainstay
Hawthorn (Crataegus species) is one of the few supplements that doubles as a prescription cardiology drug — the standardised extract WS 1442 is reimbursed for heart failure in Germany and other EU countries — and its evidence base is unusually deep for a botanical. The large SPICE trial (2,681 patients) did not cut overall events on top of standard therapy, but earlier RCTs and a Cochrane review of 855 patients showed modest gains in exercise tolerance and symptoms like fatigue and breathlessness. The crucial caveat is that those older trials predate modern heart-failure drugs, which deliver far bigger survival benefits, so hawthorn should be an add-on for symptom relief, never a replacement. The tested dose is WS 1442 900 mg/day; coordinate with a clinician because of additive effects with digoxin, nitrates, and blood-pressure medicines, and stop it two weeks before surgery.
Over a century of clinical use sits behind hawthorn, and unlike most supplements its record includes a mortality-powered trial. That depth of evidence is what makes it worth examining seriously rather than dismissing — and also what lets us be precise about where it does and doesn’t help.
The SPICE Trial
The SPICE trial (n=2,681) randomised patients with NYHA class II/III heart failure to WS 1442 900 mg/day or placebo in addition to standard therapy. Over 2 years, the primary endpoint (cardiac death, MI, hospitalisation for heart failure) was not reduced overall, but prespecified subgroup analyses showed significant reductions in sudden cardiac death in patients with LVEF 25–35%. The interpretation is that hawthorn adds modest benefit on top of modern heart failure therapy in specific subgroups.
Symptomatic Benefit
A 2008 Cochrane review of 14 earlier RCTs in mild-to-moderate heart failure (n=855) found hawthorn extract improved exercise tolerance (pressure-rate product) and reduced subjective symptoms (fatigue, dyspnoea) compared to placebo. Effect sizes were modest. These trials predated widespread ACE inhibitor and beta-blocker use, so the evidence applies most directly to an earlier era of heart failure management.
Mechanism
Hawthorn’s active compounds (oligomeric procyanidins, flavonoids) weakly inhibit phosphodiesterase-3, enhance endothelial function, and modulate ion channels. The net effect is mild positive inotropy without increased myocardial oxygen demand — pharmacologically sensible in heart failure.
Where It Fits Today
Modern heart failure therapy (beta-blockers, ACE/ARB, mineralocorticoid antagonists, SGLT2 inhibitors, sacubitril/valsartan) provides very large mortality benefits. Hawthorn should never replace these. As an add-on for symptomatic relief in patients already on optimal therapy, the evidence is modest but supportive. WS 1442 at 900 mg/day is the tested dose.
Safety
Well tolerated in trials — main side effects are mild GI upset and occasional dizziness. Some additive effects with digoxin, nitrates, and antihypertensives; coordinate with prescribing clinician. Stop 2 weeks before surgery due to theoretical effects on cardiac electrophysiology.
Sources
- Holubarsch CJF, Colucci WS, Meinertz T, Gaus W, Tändler B (SPICE Trial Study Group). "The efficacy and safety of Crataegus extract WS 1442 in patients with heart failure: the SPICE trial." European Journal of Heart Failure, 2008;10(12):1255–1263. PMID 19019730.
- Pittler MH, Guo R, Ernst E. "Hawthorn extract for treating chronic heart failure." Cochrane Database of Systematic Reviews, 2008;(1):CD005312. PMID 18254076.
- Koch E, Malek FA. "Standardized extracts from hawthorn leaves and flowers in the treatment of cardiovascular disorders — preclinical and clinical studies." Planta Medica, 2011;77(11):1123–1128.